Use of non-nucleoside analogues together with rifampin in HIV patients with tuberculosis

HIV Clinical Trials

Volumn 12, Issue 3, 2011, Pages 171-174

  Villar, J ^a   Sanchez P ^a   Gonzalez A ^a   Sorli, L ^a   Montero, M M ^a   Guelar, A ^a   Sole E ^a   Lopez J L ^a   Knobel, H ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

body weight; efavirenz; nevirapine; rifampin; tuberculosis

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RIFAMPICIN;

ARTICLE; CONFIDENCE INTERVAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT FAILURE; TUBERCULOSIS;

BENZOXAZINES; BODY WEIGHT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; TREATMENT FAILURE; TUBERCULOSIS;

EID: 79959391048     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1203-171     Document Type: Article

References (16)

1. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis. Clin Infect Dis. 1999; 28:419-430 (Pubitemid 29242513)
2. US Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. http://AIDSinfo.nih.gov. Accessed December 1, 2009
3. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA). Guidelines for the treatment of HIVinfected adults with antiretroviral therapy (2008). HIV Med. 2006;7:487-503
4. GeSIDA-SEIMC. Directrices para el tratamiento de la tuberculosis en pacientes con VIH. February 2009
5. Centers for Disease Control and Prevention. Prevention and treatment of TB among patients infected with HIV: principles of therapy and revised recommendations. Atlanta, GA: Author; 2008
6. Sathia L, Obiorah I, Taylor G, et al. Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients. AIDS Res Hum Retroviruses. 2008;24:897-901
7. Manosuthi W, Mankatitham W, Lueangniyomkul A, et al. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med. 2008;9:294-299 (Pubitemid 351517276)
8. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when co administered with rifampicin-based antitubercular therapy. JAMA. 2008;300:530-539
9. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrationsand efficacies between 2 nonnucleoside reversetranscriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis. 2009;48:1752-1759
10. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in coinfected HIV and tuberculosis patients receiving rifampin. Antimicrob Agents Chemother. 2009;53:4545-4548
11. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defi c Syndr. 2001;28:450-453 (Pubitemid 34033196)
12. Cohen K, Grant A, Dandara C, et al. Effect of rifampicinbased antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther. 2009;14:687
13. Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008;13:675
14. Gross R, Aplenc R, Tenhave T, et al. Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defi c Syndr. 2008;49:336
15. Kwara A, Lartey M, Sagoe KW, et al. Pharmacokinetics of efavirenz when co-administrated with rifampin in TB/VIH co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol. 2008;48(9):1032-1040
16. Sterling TR, von Reyn CF, et al. Treatment of tuberculosis in the HIV-infected patient Uptodate June 2010